Juniper Pharmaceuticals, Inc. Common Stock
JNP
JNP was delisted on the 13th of August, 2018.
44 hedge funds and large institutions have $27.9M invested in Juniper Pharmaceuticals, Inc. Common Stock in 2015 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 14 increasing their positions, 12 reducing their positions, and 7 closing their positions.
54% more capital invested
Capital invested by funds: $18.1M → $27.9M (+$9.75M)
53% more call options, than puts
Call options by funds: $680K | Put options by funds: $444K
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
17% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 12
5% more funds holding
Funds holding: 42 → 44 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Cadence Capital Management
Boston,
Massachusetts
|
+$1.15M |
| 2 |
PA
Perceptive Advisors
New York
|
+$339K |
| 3 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$281K |
| 4 |
WCM
Wedge Capital Management
Charlotte,
North Carolina
|
+$258K |
| 5 |
PP
PDT Partners
New York
|
+$116K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DMK
David M. Knott
|
-$415K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$300K |
| 3 |
SKK
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
-$127K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$92.8K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$85K |
JNP Hedge Fund Activity: Q2 2015 in Review
44 of the 3,713 institutional investors tracked by Wall St. Rank reported a position in Juniper Pharmaceuticals, Inc. Common Stock (JNP) for Q2 2015, worth a combined $27.9M — up 54% from $18.1M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new JNP positions and 7 closed out — a net gain of 2 holders — while 14 added to existing stakes and 12 trimmed.
The largest buyer was Cadence Capital Management, opening a new position worth an estimated $1.15M. The largest seller was David M. Knott, exiting entirely with an estimated $415K sold.
- 44 institutional investors held Juniper Pharmaceuticals, Inc. Common Stock (JNP) as of Q2 2015, up from 42 in Q1 2015.
- Funds reported $27.9M of Juniper Pharmaceuticals, Inc. Common Stock stock for Q2 2015, up 54% quarter-over-quarter.
- 9 funds opened new Juniper Pharmaceuticals, Inc. Common Stock positions in Q2 2015 and 7 closed out, a net change of +2 holders.
- The largest Juniper Pharmaceuticals, Inc. Common Stock buyer in Q2 2015 was Cadence Capital Management, an estimated $1.15M added.
- The largest Juniper Pharmaceuticals, Inc. Common Stock seller in Q2 2015 was David M. Knott, an estimated $415K sold.
Based on aggregated 13F filings for Q2 2015.